This week in Drug Discovery (10-14 August 2026)
News round-up for 10-14 August by Diana Turner, Content Team at DDW.
This week’s news round-up highlights new discoveries in cancer research, including the first trial of a new type of immunotherapy, an immune cell finding that could transform cancer treatment, and a groundbreaking drug for a common cell therapy side effect.
The top stories:
New therapy targets blocks to immunotherapy success in solid tumours
Dispatch Bio has dosed the first participant in a Phase I clinical trial evaluating the safety and efficacy of DISP-10 in adult participants with advanced gastrointestinal (GI) cancers, including colorectal cancer, gastric adenocarcinoma, oesophageal adenocarcinoma, and gastroesophageal adenocarcinoma.
Award validates collaborative breast cancer research project
A collaborative breast cancer research project has received funding through the Fiscal Year 2025 Breast Cancer Research Program Breakthrough Award, administered by the Congressionally Directed Medical Research Programs (CDMRP).
Scientists unmask immune cells that supercharge the fight against cancer
A little‑known group of hard-to-find immune cells could help transform cancer treatment, scientists at the University of Manchester’s Cancer Research UK Manchester Institute, have found.
Radiotherapeutic study shows low exposure to healthy organs
Radiopharmaceuticals company Oncoinvent has announced the publication of clinical dosimetry data for Radspherin in ovarian and colorectal cancer in the Journal of Nuclear Medicine.
New drug could improve access to immunotherapies
A UK-led clinical trial has opened at The Christie NHS Foundation Trust in Manchester to test a new drug that could make immunotherapy safer and more accessible for patients with multiple myeloma.
